Treg depletion therapy is expected to be the next novel tumor immunotherapy, and several clinical trials targeting Tregs using mAbs, such as CD25 (daclizumab)28 and CCR4 (mogamulizumab)18, have been conducted. The gene discussed is CCR4; the disease is neoplasm.